AMH and neoplasm: The secondary endpoint was overall survival (OS) and tumor-free survival (TFS) The authors showed a significantly lower POI rate in the GnRHa group compared to chemotherapy only (10.3% vs. 44.5%, p < 0.001) and the AMH recovery rate was better in GnRHa group (15 of 25 vs. 6 of 44; p < 0.001).